Previous close | 28.24 |
Open | 28.20 |
Bid | 27.10 x 20000 |
Ask | 27.52 x 20000 |
Day's range | 27.90 - 28.50 |
52-week range | 27.70 - 38.40 |
Volume | |
Avg. volume | 138 |
Market cap | 179.307B |
Beta (5Y monthly) | 0.15 |
PE ratio (TTM) | 15.25 |
EPS (TTM) | 1.83 |
Earnings date | 25 Jul 2024 |
Forward dividend & yield | 1.30 (4.61%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | 52.44 |
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Q1 2024 Sarepta Therapeutics Inc Earnings Call
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.